Cardiovascular risk and sildenafil.

@article{Kloner2000CardiovascularRA,
  title={Cardiovascular risk and sildenafil.},
  author={Robert A. Kloner},
  journal={The American journal of cardiology},
  year={2000},
  volume={86 2A},
  pages={57F-61F}
}
Sildenafil citrate is the first oral agent approved for the treatment of erectile dysfunction (ED); other oral agents are in the process of development. Because the mechanism of action of many of these agents involves vasodilation, there is a potential for interaction with the cardiovascular system. Sildenafil inhibits phosphodiesterase-5 (PDE-5) which is… CONTINUE READING